Can EU Distributors Relabel Sterile Devices Without Becoming the Manufacturer?

Start with the operator, device and proposed change

This guide is for EU importers, distributors and supplier-quality teams deciding whether to translate an IFU or change the sales carton around a sterile single-use device. It addresses the downstream change decision, rather than providing a country-language list or confirming authorization for a particular product. A destination-language requirement can make translation necessary, but the exact Member State, user group and proposed information must be checked before work starts.¹

Article 16(1) can place manufacturer obligations on an importer, distributor or other person that supplies a device under its own name, changes its intended purpose, or modifies it in a way that may affect compliance. Own-name supply has a specific agreement exception, discussed below. A label change therefore needs a role assessment before it becomes a warehouse task; a substantial physical redesign is not the only relevant trigger.⁴⁷⁹

Article 16(2) identifies limited information and outer-packaging activities that are not treated as compliance-affecting modifications under Article 16(1)(c). It is not a general exemption from device conformity, importer or distributor duties. The two activities concern devices already placed on the market:¹²⁹

• Article 16(2)(a): Providing, including translating, manufacturer information required under Annex I Section 23, and further information necessary to market the device in the relevant Member State.¹²
• Article 16(2)(b): Necessary outer-packaging changes, including pack-size changes, under conditions that cannot affect the original condition of the device. Necessity must be assessed for the actual destination and proposed change.¹²

Sources were reviewed on 27 October 2026 against the MDR consolidated text dated 19 July 2026.⁹ MDCG 2021-26 addresses scope and notifications; MDCG 2021-23 addresses QMS certification; MDCG 2021-27 Rev.1 and MDCG 2022-7 clarify adjacent importer and identifier responsibilities. These documents remain listed on the Commission guidance index. MDCG guidance is nonbinding and cannot replace the legislation or a transaction-specific regulatory assessment.⁶

Which proposed changes are actually within Article 16?

A distributor must determine whether a proposed packaging modification falls under Article 16(2), another regulatory mechanism, or outside the scope of distributor activities entirely. Not every label addition or carton change follows the same compliance pathway.

First, separate importer identification from translation. Article 13(3) requires importer contact details on the device, packaging or an accompanying document. MDCG 2021-27 Rev.1 Q7–8 explains that those details must reach the end user and additional labels must not obscure manufacturer information. A sticker solely supplying importer details is not automatically the independent translation/repackaging route. Its placement still needs to preserve device compliance.³

Second, distinguish a logistics split from a changed sales pack. MDCG 2021-26 Q4 treats splitting shipping quantities as outside Article 16(2) when the device’s outer packaging is unaffected. Here, outer packaging means the packaging intended by the manufacturer to reach the end user; warehouse names such as “master carton” do not settle the question. Distributor checks, including CE marking and accompanying manufacturer information, continue.¹

Third, combining devices into a new procedure kit requires a separate assessment. Adding drapes or instruments from other manufacturers to create a clinical kit is not simply changing the outer carton of the same device. Review the separate rules for procedure-kit assembly before treating the operation as Article 16 relabelling.¹⁷

Fourth, assess own-brand supply separately. MDCG 2022-7 Section B Q2 explains the Article 16(1)(a) exception: an agreement may leave the original manufacturer identified as such on the label and responsible for the manufacturer requirements. Neither an added distributor logo nor the words “private label” alone resolve the role. Obtain the actual label and agreement; an ordinary purchase order is not evidence that this exception has been established.⁴⁹

Does sterile packaging rule out relabeling?

Do not assume sterile devices are categorically excluded from the limited Article 16 route. Equally, do not assume that an intact blister makes every outer-carton change permissible. BSI’s certification FAQ already explains the sterile-packaging qualification and manufacturer-control distinction; the practical task is to apply them to the actual pack and operator.²⁷

MDCG 2021-23 footnote 3 reproduces the sterile-device condition in Article 16(2)(b): adverse effects on packaging necessary to maintain sterility are presumed to affect the original condition. Identify that packaging from manufacturer evidence, rather than deciding by appearance or calling every external box “non-sterile packaging.”²

For a common individually packaged sterile device, distinguish the following packaging functions. The manufacturer’s documented hierarchy controls the assessment; not every product has three separate physical layers.

• Sterile barrier: The validated packaging that maintains sterility. It may be a pouch, blister or another system. A material name does not establish barrier performance.
• Outer sales packaging: Packaging supplied to the end user around the sterile unit. It can also protect the barrier during handling and transport; replacing it must not reduce that protection.
• Shipping container: A logistics unit. Splitting its contents is a different decision when manufacturer-intended device packaging and information remain unaffected.¹²

If the proposal would open, damage or otherwise adversely affect packaging needed to maintain sterility, stop the Article 16(2) routing exercise and escalate to the legal manufacturer and qualified regulatory/quality staff. A distributor certificate is not permission to reseal or resterilize the pack. Affected stock requires a documented disposition; this guide supplies no rework or return-to-service procedure.²

Where the sterile barrier remains unaffected, a necessary outer-pack change may qualify. The assessment must still cover original device condition, protective packaging, correct information, traceability, operator controls and the applicable certificate/notice duties. Do not describe porous sterile-barrier materials as hermetic, or assume that replacing a protective carton is harmless merely because the seal is intact.¹²

Who controls the translation and pack change?

Start by asking who approves, controls and releases the changed information or pack. The company paying for translation is not necessarily the company controlling the activity. The following pathways are conditional; neither can be established from a distributor agreement heading alone.

Pathway A: Manufacturer-controlled work. MDCG 2021-26 excludes operators subcontracted to perform relabelling or repackaging on behalf of and under the manufacturer’s control from Article 16(2)–(4).¹ As practical evidence of that control, request approved artwork and IFU revisions, the responsible sites, a quality agreement defining approval and release, and a process for subsequent changes. These are recommended review records, not a prescribed regulatory form. Manufacturer awareness or an informal email does not establish the whole control arrangement.

Pathway B: Independent importer/distributor work. For qualifying independent work on MDR devices, assess all of Article 16(2)–(4): permitted activity and preserved condition, the QMS, notified-body certification and advance notice. The responsible operator must control its translators and packagers. Manufacturer consent does not by itself substitute for these duties or demonstrate Pathway A.¹²

Legacy-device exception. MDCG 2021-26 Q2 states that Article 16(3) and (4) do not apply to legacy devices. Do not infer legacy eligibility from a CE logo, a certificate’s age or a supplier’s description. Obtain current evidence of the applicable transitional route and have the regulatory lead confirm it before relying on the exception. This is not a blanket exclusion from original-condition, accurate-information or other applicable distribution responsibilities.¹⁷

Which certificate must cover the activity and device type?

For the independent MDR route, Article 16(4) requires a certificate attesting that the importer’s or distributor’s QMS meets Article 16(3). The notified body must be designated for the relevant device types. This is separate from the manufacturer’s device conformity assessment; it is not a fresh product approval.²

Under MDCG 2021-23 (Section 3), an Article 16 compliant QMS must incorporate established operating procedures governing:²

• Accurate, current translations, with personnel and checks appropriate to the work.
• Packaging processes that preserve original condition, including defect prevention and handling controls.
• Traceability connecting devices, original lots, changed packaging and label/IFU revisions.
• Complaint handling, corrective actions and recall arrangements, including procedures ensuring that the importer or distributor is informed promptly of manufacturer safety or conformity actions.²⁹
• Supplier/subcontractor controls, document and record control, internal audits and management review.²
• Operator identification: Article 16(3) also requires the activity performed and the operator’s identifying/contact information on the device or, where impracticable, its packaging or an accompanying document.⁹

Check three different certificate questions before accepting the proposed operator:

1. Is it the required certificate? ISO 13485 certification may support a QMS, but it is not the Article 16(4) attestation. Ask for the actual Article 16 certificate and read its conditions. A product CE certificate cannot substitute for it.²⁷

2. Is it issued to the operator doing the work? Compare the named importer or distributor, address, activities and any relevant site arrangements with the quotation and subcontract map. Do not assume that a manufacturer’s certificate or another group company’s certificate covers the proposed operation.²

3. Does its scope cover the device types and activities? MDCG 2021-23 Section 5 calls for clear device-type scope and the covered relabelling/repackaging activities. Match these to the proposed work, together with validity and any restrictions. Class I is not automatically exempt from this independent route; MDCG 2021-26 Q10–11 directs operators to the appropriate notified-body designation.¹²

What belongs in the notice and change register?

For the applicable independent route, certification and advance notification are separate duties. Plan both against the proposed availability date.⁹

For the applicable independent route, inform the manufacturer and destination Member State competent authority at least 28 days before making the relabelled or repackaged device available. In that period, submit the Article 16(4) certificate to the authority. A sample or mock-up, including translated label and IFU, is supplied to either recipient on request. Keep the notice, recipient and delivery evidence together; confirm the authority’s current submission channel before scheduling supply.¹⁵⁹

MDCG 2021-26 Q7 treats notice as a first-time activity rather than a unit-by-unit or batch-by-batch requirement. Q8 provides separate, non-exhaustive trigger lists for the manufacturer and authority. Keep recipient-specific records instead of treating every change as one undifferentiated notification event:¹

• Manufacturer: a previously unnotified Member State, device or translation language.¹
• Concerned authority: a previously unnotified device or language; changed supplied information or outer packaging; certificate changes, including renewal; or a changed notified body.¹
• Change assessment: record which recipient must receive what, and confirm timing for the actual change. The guidance does not establish a universal rule that a specimen request or every revised document automatically restarts one identical clock for all recipients.¹

MDCG 2021-26 Q12 says the manufacturer’s batch number cannot be changed and should appear on the label. Additional sub-lot information can support traceability. Keep the original batch identity visible and link it to the changed-pack records; an internal work-order number does not replace that identity or justify a new expiry date.¹

Which evidence should a sterile-device distributor request?

Before ordering translation or packaging services, ask for the original pack and current manufacturer information. Review the proposed label alongside authorised-representative artwork checks. Keep symbol selection and Article 16 operator qualification as separate questions: correct symbols do not prove that the pack-change operator is authorized.

The qualification protocol should follow four sequential evidence gates:

1. Freeze the proposal. Identify the exact device/size, Member State, saleable quantity, source IFU revision and change. Request original/proposed pack photographs and manufacturer packaging specifications. Record why the change is necessary for that market.¹
2. Agree the control route. Ask whether the manufacturer will control the localized artwork and work. Request evidence of approvals, subcontractor oversight and release. Otherwise assess the applicable independent route, including any substantiated legacy exception.¹²
3. Define acceptance evidence. Specify translation accuracy and currency checks, label legibility/adhesion under the product’s actual labelled conditions, retained protective performance and original-lot linkage. Back-translation or additional clinical review may be chosen as risk-based checks; the cited guidance does not mandate a universal method, adhesive grade, temperature range or carton-seal location.²
4. Reconcile identity and availability. Have the responsible regulatory/UDI lead confirm package identifiers and readable carriers for the actual changed configuration. Complete applicable certificate and notice records before setting the supply date; a scannable code alone does not establish compliance.¹⁴

Worked example: a translated IFU inside a different sales carton

Suppose a distributor holds individually sterile-packed consumables already placed on the EU market and wants a destination-language IFU with a smaller sales carton. This is an illustrative scenario, not an audited VEMERIX shipment. First determine whether the box being changed is manufacturer-intended device packaging or merely a logistics container. If it is a sales pack, record the local need for the change and obtain packaging evidence that the new arrangement preserves original condition and protection.¹²

Then resolve control. If the manufacturer actually adopts and controls the localized pack and subcontracted work, document that arrangement. If the distributor acts independently on MDR devices, request its applicable Article 16 certificate and plan the required notices. A claimed legacy route needs its own documented basis. In every case, pause if the IFU revision is uncertain, the original lot would be hidden or packaging protection cannot be substantiated. These are evidence decisions to make before the commercial delivery promise.¹²

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.

The VEMERIX sterile blister-packed circumcision ring provides a relevant example: its public specifications describe adult and pediatric variants, EO sterilization and individual sterile blister packaging.⁸ Those facts do not establish the current EU conformity route, actual packaging materials, approved translations or Article 16 arrangements. Obtain the current product-specific documents for the exact model and destination.

Ask whether manufacturer-controlled localization is available for the exact model and market, and how the work would be controlled. Compare the offered scope, document availability, responsibilities and costs before choosing an arrangement. Product-specific EU conformity and the proposed activity still need verification; the brand or factory location alone cannot settle either question.

For a quality and regulatory document discussion, provide the destination Member State, exact model/size, original pack photos, proposed language or carton change, intended work operator and expected volume. Request the current label and IFU evidence pack and ask which conformity, packaging and control documents are available for review. Agree the evidence and responsibilities before translation, repackaging or distribution proceeds.

Frequently Asked Questions

Does ISO 13485 certification replace an Article 16(4) certificate?

No. ISO 13485 certification and Article 16(4) certification are separate. Where the independent MDR route applies, obtain the notified-body certificate that attests to the operator’s Article 16(3) QMS and matches the device types and activities. Do not use the product manufacturer’s certificate as a substitute.²⁷

Does every continuing batch need a fresh 28-day notice?

No. MDCG 2021-26 Q7 describes first-time notification rather than repeated batch notices. Later changes require assessment against Q8’s recipient-specific lists. A new destination, device or language and changes to the authority’s notified information or certificate may require further notice; do not assume every change has identical recipients and timing.¹

Is an importer-address sticker the same as translating an IFU?

No. Importer identification is an Article 13(3) duty, with contact information reaching the end user and manufacturer information unobscured. Independent IFU translation is a different activity. Assess whether Article 16(2)–(4) applies, including manufacturer control and any substantiated legacy exception.¹³

Can the original manufacturer lot number be replaced with a distributor lot?

No. The manufacturer’s batch number must be retained on the label. MDCG 2021-26 Q12 allows additional traceability information such as a distributor sub-lot. Keep both identities linked; do not imply that repackaging creates a new manufacturer batch or renewed shelf life.¹

Does a manufacturer-controlled subcontract need an Article 16 certificate?

MDCG 2021-26 excludes subcontracted work performed on behalf of and under the manufacturer’s control from Article 16(2)–(4). Establish actual control, approved revisions and release responsibilities. The exclusion does not remove other applicable manufacturer, importer or distributor obligations.¹

Does an Article 16 certificate authorize opening a sterile blister?

No. An Article 16(4) certificate is not authority to open or rework packaging needed to maintain sterility. Opening, damage or another adverse effect triggers the sterile-condition presumption in Article 16(2)(b), reproduced in MDCG 2021-23. Hold the proposal and seek manufacturer and qualified regulatory/quality assessment.²

What happens if a competent authority does not respond within the 28-day period?

Article 16(4) is an advance-notification requirement, not a product-approval certificate. Authority silence does not establish compliance. Before availability, the operator must satisfy the applicable route, complete certificate submission and any requested sample/mock-up follow-up, and resolve objections or restrictions. Confirm destination practice for unresolved requests; this guide does not establish a universal approval-by-silence or clock-reset rule.¹⁵